The ROYALTY PHARMA is a privately held investment adviser that advises $40.32Bn in regulatory assets under management held in 2 SEC fund types across 2 investment strategies. ROYALTY PHARMA is a Private Fund A private fund manager is a manager whose >=75% of total assets under management are in private funds (privately offered pooled vehicles for accredited or qualified investors, generally accessed through placements with higher minimums, restricted eligibility, and negotiated terms) Manager. Assets increased by 146.69% over the last 5-years.
The Group has been registered with the SEC for 14.35 years and is comprised of 3 filing and 0 relying advisers. They operate out of 1 office location with their Headquarters at 110 EAST 59TH STREET, NEW YORK, NEW YORK. The Group has not been subject to regulatory enforcement actions. They are regulated by 1 US and Non-US bodies.
They have 93 employees comprised of 49 investment and 44 non-investment staff. The total number of Employees increased by 102.17% over the last 5-years.
Their $40.32Bn in assets advised are owned by 9 private funds, 0 public funds and BDCs and 0 other accounts. Assets of Pooled Investment Vehicles (Not IC or BDC) clients total $40.32Bn or 100% of Total Assets.
The Group's top investment strategies include Traditional LBO and FI/Credit - Diverse, representing 54.77% and 45.23% of total assets, respectively.
They advise 1 types of clients, top clients are Pooled Investment Vehicles (Not IC or BDC).
The Group uses 1 Fund Administrators, 1 Fund Auditors, 0 Prime Brokers, 1 Custodians and 0 Marketers. It does not report a third-party Fund Administrator in 0 private funds with $0 in assets.
The Group discloses fixed fees, management fees and performance-based fees.
ROYALTY PHARMA names 0 sub-advisers to 0 different funds advised by the group. The Group has been named as the sub-adviser to 0 funds.